High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Katsurada, Kenichi ^a   Ichida, Masaru ^a   Sakuragi, Masako ^a   Takehara, Megumi ^a   Hozumi, Yasuo ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Anthracycline; Biomarker; Cardiac Troponin; Cardiotoxicity; Chemotherapy; Echocardiography; Heart failure; Trastuzumab

Indexed keywords

EID: 84919722741     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-620     Document Type: Article

References (24)

1. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.N Engl J Med 1996, 335:1342–1349. 10.1056/NEJM199610313351802
2. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS, Committee on Standardization of Markers of Cardiac Damage of the IFCC: Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome.Clin Chem 2005, 51:810–824. 10.1373/clinchem.2004.046292
3. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS: Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.N Engl J Med 2002, 346:2047–2052. 10.1056/NEJMoa013456
4. Chen MH, Kerkela R, Force T: Mechanism of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.Circulation 2008, 118:84–95. 10.1161/CIRCULATIONAHA.108.776831
5. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL: Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.JAMA 2010, 304:2494–2502. 10.1001/jama.2010.1708
6. Donnelly R, Millar-Craig MW: Cardiac troponins: IT upgrade for the heart.Lancet 1998, 351:537–539. 10.1016/S0140-6736(05)78549-4
7. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS: The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.J Am Coll Cardiol 2011, 57:2263–2270. 10.1016/j.jacc.2010.11.063
8. Fehr T, Knoflach A, Ammann P, Pei P, Binswanger U: Differential use of cardiac troponin T versus I in hemodialysis patients.Clin Nephrol 2003, 59:35–39. 10.5414/CNP59035
9. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA: Analytical validation of a high-sensitivity cardiac troponin T assay.Clin Chem 2010, 56:254–261. 10.1373/clinchem.2009.132654
10. Hudis CA: Trastuzumab — mechanism of action and use in clinical practice.N Engl J Med 2007, 357:39–51. 10.1056/NEJMra043186
11. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, Investigators V-HFT: Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.Circulation 2007, 116:1242–1249. 10.1161/CIRCULATIONAHA.106.655076
12. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group: Fragmin during Instability in Coronary Artery Disease.N Engl J Med 2000, 343:1139–1147. 10.1056/NEJM200010193431602
13. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, Peruzzi M, Frati G, Palazzoni G: Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.Am J Cardiol 2013, 112:1980–1984. 10.1016/j.amjcard.2013.08.026
14. Melanson SE, Morrow DA, Jarolim P: Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity.Am J Clin Pathol 2007, 128:282–286. 10.1309/Q9W5HJTT24GQCXXX
15. Nishimura RA, Tajik AJ: Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone.J Am Coll Cardiol 1997, 30:8–18. 10.1016/S0735-1097(97)00144-7
16. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E, Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators: A sensitive cardiac troponin T assay in stable coronary artery disease.N Engl J Med 2009, 361:2538–2547. 10.1056/NEJMoa0805299
17. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Šaltytė Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald E, Investigators PEACE: Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.J Am Coll Cardiol 2013, 61:1240–1249. 10.1016/j.jacc.2012.12.026
18. Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA: High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.Breast Cancer Res Treat 2012, 134:291–298. 10.1007/s10549-012-2039-z
19. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M: Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.Am J Cardiol 2011, 107:1375–1380. 10.1016/j.amjcard.2011.01.006
20. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M: Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.Circ Cardiovasc Imaging 2012, 5:596–603.
21. Tsutamoto T, Kawahara C, Yamaji M, Nishiyama K, Fujii M, Yamamoto T, Horie M: Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure.Eur J Heart Fail 2009, 11:653–658. 10.1093/eurjhf/hfp072
22. Tsutamoto T, Kawahara C, Nishiyama K, Yamaji M, Fujii M, Yamamoto T, Horie M: Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure.Am Heart J 2010, 159:63–67. 10.1016/j.ahj.2009.10.022
23. Vasan RS, Levy D: The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview.Arch Intern Med 1996, 156:1789–1796. 10.1001/archinte.1996.00440150033003
24. Yeh ET, Bickford CL: Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.J Am Coll Cardiol 2009, 53:2231–2247. 10.1016/j.jacc.2009.02.050